(GLTO)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Galecto, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, fibroz, saraton, yalligʻlanish va boshqa shu kabi kasalliklarni davolash uchun molekulyar dorilarni ishlab chiqadi. Kompaniya ENL-YEATS va FLT3 ning preklinik kichik molekulyar er-xotin inhibitori boʻlgan GB3226 va koʻplab onkologik va jigar kasalliklari koʻrsatkichlarini davolash uchun galectin-3 ning ogʻiz orqali qabul qilinadigan kichik molekulyar inhibitori boʻlgan GB1211 ni ishlab chiqadi. Galecto, Inc. 2011 yilda tashkil etilgan va shtab-kvartirasi Daniyaning Kopengagen shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Becker Hewes M.D. | Chief Medical Officer |
| Dr. Hakon Leffler M.D., Ph.D. | Co-Founder |
| Mr. Garrett Winslow Esq. | Senior VP, General Counsel & Corporate Secretary |
| Mr. Sherwin Sattarzadeh | Interim Principal Executive Officer & COO |
| Mr. Ulf J. Nilsson Ph.D. | Co-Founder |
| Ms. Lori C. Firmani | Chief Financial Officer |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-12 | 8-K | glto-20260112.htm |
| 2026-01-06 | 8-K | glto-20251231.htm |
| 2026-01-02 | S-8 | glto-20260102.htm |
| 2025-12-16 | S-3 | d60916ds3.htm |
| 2025-12-09 | 8-K/A | glto-20251110.htm |
| 2025-11-21 | D | |
| 2025-11-10 | 8-K | d53983d8k.htm |
| 2025-11-06 | 10-Q | glto-20250930.htm |
| 2025-08-05 | 10-Q | glto-20250630.htm |
| 2025-06-20 | 8-K | glto-20250618.htm |